Treatment Signs Ocean Medical Agreement For The AI Driven Doctors Office
VANCOUVER, British Columbia, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Treatment.com International Inc. (“Treatment or the (“Company”) (CSE: TRUE • OTC: TREIF • 939.F) is a healthcare technology company with a passion for supporting consumers and health care providers globally with easy, AI-driven solutions.
Today Treatment announces the first sale of its Treatment Primary Care Module, powering the next generation of AI-assisted healthcare. Using medically built artificial intelligence, the Treatment Primary Care Module will improve all aspects of the patient / doctor experience in the medical clinic setting. Powered by the rapidly expanding Global Library of Medicine and micro service AI technologies, this new solution integrates seamlessly with the medical clinics’ EMR system. This dramatically improves the patient workflow, while aiding busy medical professionals with their clinical practice.
Instead of doctors spending valuable patient time at the keyboard, entering symptoms and other critical medical information, the Treatment AI system “pre-interviews” the patient in the comfort of their home, then builds an extremely accurate list of personalized symptoms, risk factors and possible diagnoses just as the doctor would have done. Then when the patient is seen, either in the clinic or over a video link, the doctor can simply review the AI-curated evidence and make final diagnosis and treatment recommendations more accurately and quickly.
“This is transformational,” said Dr. Rob Scott, clinic owner. “The earlier pilot proved to us that this is going to be what all providers will need to stay competitive. Since the Treatment AI system interviews the patient first and writes a report in the format I would have anyway, it saves me time, allows more productive discussions with the patient, and on many occasions, reminds our busy practitioners about diagnoses they might not have considered. This is truly the next generation of health care, and we are proud to be leading the way in partnership with Treatment.”
“This agreement ensures Ocean Medical patients and providers will be working in the doctor’s office of the future and they too will become a beacon of vision for medical clinics around the globe,” says William Sigsbee, Chief Commercial Officer, Treatment.com. “It has been a pleasure working with this visionary team and they will become a key partner for Treatment, as we release many other new products in coming months and years.”
“I am extremely proud to partner with Dr. Rob Scott and his forward-looking providers to begin a new chapter in AI-enhanced health care,” said Mr. John Fraser, CEO of Treatment. “My amazing global team of doctors and AI experts has been successful in helping providers automate the most complex part of healthcare, diagnosing and recommending treatments when we get sick - and this is just the first step in a long and exciting journey.”
Treatment.com is a disruptive healthcare technology company that is harnessing the power of AI to help global citizens improve their health through personalized recommendations and insights. Based in Vancouver with a US subsidiary, the company spent the last five years working with a team of world-class doctors, engineers, mathematicians, and AI specialists to develop a complex AI engine that leverages the most robust, personalized data to generate highly predictive and accurate insights. Treatment Mobile is a soon to be released intelligent digital health assistant which will empower people to take control of their health through an innovative mobile app, powered by Treatment’s exclusive AI engine.
For more investor information on Treatment.com please visit https://treatment.com/investors/.
Forward Looking Statement
This news release contains forward-looking statements relating to the future operations of Treatment.com, International, Inc. (Treatment) and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment’s expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
For more information:
Investor Contact: [email protected]
- Extendicare Announces December 2021 Dividend of C$0.04 per Share
- Allarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Stock Market
- Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein